CPTAC
For proteomics firms, 2022 marked a reversal from an earlier boom, but the field pushed into emerging areas like single-cell, single-molecule, and spatial analyses.
Researchers inside and outside the program said it has produced new methods and a wealth of data while helping to bolster proteomics' credibility.
NCI Names Participating Centers for Latest Clinical Proteomic Tumor Analysis Consortium Stage
The institute has awarded funding to a total of 12 sites to perform proteogenomic analyses on tumor samples and to study drug response and resistance.
NCI Launching Fourth Phase of CPTAC With Anticipated $56M in Funding
The reissuance will continue the initiative's focus on proteogenomic research and applying proteogenomics to understanding cancer drug response and resistance.
Multi-Omic Endometrial Cancer Study Reveals Novel Pathways, Treatment Targets
The study characterized aspects of the tumor immune landscape, including immunogenic alterations, neoantigens, and the immune microenvironment.